CDK4 and cancer: This oncogenic effect of p16 depends on the inhibition of CDK4/CDK6 in cancer cells where Rb is inactivated, suggesting the presence of CDK4/6 substrates that may cause cell death when phosphorylated in cells with inactivated Rb 44.